# Rapamycin in Relapsed Acute Lymphoblastic Leukemia

> **NCT00874562** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 6 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Corticosteroid
- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT00874562
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2009-11
- **Final completion:** 2016-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2016-11-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00874562

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00874562, "Rapamycin in Relapsed Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00874562. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*